A potential new prodrug for the treatment of cystinosis : Design, synthesis and in-vitro evaluationMCCAUGHAN, Bridgeen; KAY, Graeme; KNOTT, Rachel M et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 5, pp 1716-1719, issn 0960-894X, 4 p.Article

Molecular modelling and cytotoxicity of substituted anthraquinones as inhibitors of human telomeraseCAIRNS, Donald; MICHALITSI, Evangelia; JENKINS, Terence C et al.Bioorganic & medicinal chemistry. 2002, Vol 10, Num 3, pp 803-807, issn 0968-0896Article

PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosisOMRAN, Ziad; KAY, Graeme; DI SALVO, Alberto et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 1, pp 45-47, issn 0960-894X, 3 p.Article

Gel formulations for treatment of the ophthalmic complications in cystinosisBUCHAN, Barbara; KAY, Graeme; HENEGHAN, Anne et al.International journal of pharmaceutics (Print). 2010, Vol 392, Num 1-2, pp 192-197, issn 0378-5173, 6 p.Article

Design of telomerase inhibitors for the treatment of cancerCAIRNS, Donald; ANDERSON, Rosaleen J; PERRY, Philip J et al.Current pharmaceutical design. 2002, Vol 8, Num 27, pp 2491-2504, issn 1381-6128, 14 p.Article

Suppository Formulations as a Potential Treatment for Nephropathic CystinosisBUCHAN, Barbara; KAY, Graeme; MATTHEWS, Kerr H et al.Journal of pharmaceutical sciences. 2012, Vol 101, Num 10, pp 3729-3738, issn 0022-3549, 10 p.Article

Folate pro-drug of cystamine as an enhanced treatment for nephropathic cystinosisOMRAN, Ziad; KAY, Graeme; HECTOR, Emma E et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 8, pp 2502-2504, issn 0960-894X, 3 p.Article

Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosisOMRAN, Ziad; MOLONEY, Kevin A; BENYLLES, Amina et al.Bioorganic & medicinal chemistry. 2011, Vol 19, Num 11, pp 3492-3496, issn 0968-0896, 5 p.Article